An open-label efficacy trial of escitalopram for night eating syndrome
An open-label efficacy trial of escitalopram for night eating syndrome
复制标题
DOI：
10.1016/j.eatbeh.2013.02.001
复制
发表时间：
2013-04-01
期刊：
影响因子：
2.8
通讯作者：
Stunkard, Albert J.
中科院分区：
文献类型：
--
作者：
Allison, Kelly C.;Studt, Stacia K.;Stunkard, Albert J.
目的：夜间进食综合征（内斯）是一种需要有效治疗的疾病。选择性5-羟色胺再摄取抑制剂在以前的试验中已经显示出疗效，所以我们试图扩大我们对艾司西酞普兰在当前trial.Method的疗效的理解：31名成人内斯参加了为期12周的艾司西酞普兰的开放标签试验。结果测量包括夜间进食症状量表（NESS），晚餐后每日摄入量的百分比（%摄入量）和夜间进食次数/周（NI），体重，总觉醒次数/周，情绪和生活质量。混合效应模型用于评估随时间的变化。结果：从第0周至第12周，NESS（30.2至15.2）、%摄入量（46%至17%）、NI（5.8至1.2）、体重（90.2至88.6 kg）、觉醒次数（8.1至2.7）和BDI-II（12.1至7.7）显著降低。性别、年龄、种族或精神共病状态的结局无显著差异。讨论：艾司西酞普兰的开放标签试验显示与内斯相关的症状显著减少。有必要进行随机对照试验来检验这些发现。
Objective: Night eating syndrome (NES) has become increasingly recognized as a disorder in need of effective treatments. Selective serotonin reuptake inhibitors have shown efficacy in previous trials, so we sought to expand our understanding of the efficacy of escitalopram in the current trial.Method: Thirty-one adults with NES participated in a 12-week open-label trial of escitalopram. Outcome measures included the Night Eating Symptom Scale (NESS), percent of daily intake after the evening meal (% intake) and number of nocturnal ingestions/week (NI), weight, total awakenings/week, mood, and quality of life. Mixed-effects models were used to assess change over time.Results: Significant reductions were observed from week 0 to week 12 for the NESS (30.2 to 15.2), % intake (46% to 17%), NI (5.8 to 1.2), weight (90.2 to 88.6 kg), awakenings (8.1 to 2.7), and BDI-II (12.1 to 7.7). Outcomes did not differ significantly by gender, age, race, or psychiatric co-morbidity status. Eighteen of 31 completed 12 weeks of treatment.Discussion: This open-label trial of escitalopram showed significant reductions in symptoms associated with NES. Randomized controlled trials are warranted to test these findings.